Zhuhai Energy

Zhuhai Energy is a clinical-stage biopharmaceutical company based in Zhuhai, China, specializing in the development of innovative therapies for metabolic and endocrine diseases. The company's primary focus is on the research and commercialization of recombinant protein drugs, particularly targeting fibroblast growth factor pathways and incretin receptors. Its lead programs are directed toward high-prevalence conditions such as nonalcoholic steatohepatitis (NASH), type 2 diabetes, and obesity. Zhuhai Energy leverages advanced protein engineering to create long-acting biologics with improved therapeutic profiles. The company aims to address significant unmet medical needs in the global metabolic health market through its robust internal R&D pipeline.